1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
6 citations
,
October 2013 in “Expert Review of Dermatology” Psychotropic medications can cause skin problems, including serious conditions, and patients should be monitored closely.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
May 2022 in “Reactions Weekly”
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
July 2024 in “Journal of Investigative Dermatology” Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
2 citations
,
April 2019 in “Journal of Internal Medicine” Men using steroids or finasteride to look more attractive may harm their fertility and sexual function, creating a paradox where they seem fit but may be less able to reproduce.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
30 citations
,
August 2018 in “Dermatology and Therapy” Better-designed, long-term studies are needed to optimize treatment for trichotillomania and trichophagia.
September 2024 in “Dermatology Reports” Sonidegib often causes hair loss, and LC-OCT helps identify early signs.
July 2025 in “Medical Science” Anabolic steroids and SARMs can cause serious liver damage.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
24 citations
,
May 2010 in “Veterinary dermatology” Oral ciclosporin A and topical treatments both reduce hair loss and scaling in dogs with sebaceous adenitis, but using both together is most effective.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
January 2026 in “Cronfa (Swansea University)” Finasteride and dutasteride may increase the risk of depression and suicidality, so patients should be monitored closely.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
20 citations
,
March 1990 in “Archives of Dermatology” Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
July 2024 in “Forum Dermatologicum” October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Protetox is claimed to be an effective weight loss supplement with positive reviews.
23 citations
,
November 2018 in “International Journal of Molecular Sciences” Deoxyshikonin helps wounds heal faster in diabetic mice.
1 citations
,
April 2004 in “The Journal of Urology” Finasteride may help treat recurrent priapism in sickle cell anemia.
47 citations
,
April 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
June 2019 in “Reactions Weekly”
7 citations
,
January 2001 in “PharmacoEconomics” The article concludes that a balance is needed between individual healthcare needs and societal resources when it comes to lifestyle drugs, with a call for compassionate policy application.